Sei Investments Co. Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Sei Investments Co. boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 33.2% during the 1st quarter, Holdings Channel reports. The firm owned 411,962 shares of the medical equipment provider’s stock after buying an additional 102,694 shares during the quarter. Sei Investments Co.’s holdings in Zimmer Biomet were worth $37,249,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. boosted its stake in Zimmer Biomet by 9.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after buying an additional 13,883 shares during the last quarter. Douglas Lane & Associates LLC increased its stake in Zimmer Biomet by 6.7% in the 4th quarter. Douglas Lane & Associates LLC now owns 460,178 shares of the medical equipment provider’s stock worth $41,379,000 after acquiring an additional 28,818 shares during the last quarter. Morningstar Investment Management LLC raised its holdings in shares of Zimmer Biomet by 235.4% during the 4th quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider’s stock worth $5,204,000 after acquiring an additional 40,610 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of Zimmer Biomet by 257.2% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider’s stock valued at $3,091,000 after acquiring an additional 24,748 shares during the last quarter. Finally, CIBC Asset Management Inc boosted its position in shares of Zimmer Biomet by 67.6% during the 4th quarter. CIBC Asset Management Inc now owns 46,516 shares of the medical equipment provider’s stock valued at $4,183,000 after acquiring an additional 18,769 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.28% of the stock is currently owned by insiders.

Zimmer Biomet Price Performance

NYSE ZBH opened at $91.35 on Monday. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $108.29. The firm has a market capitalization of $17.67 billion, a price-to-earnings ratio of 23.73, a PEG ratio of 2.69 and a beta of 0.46. The company has a fifty day moving average of $87.90 and a two-hundred day moving average of $89.79.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.23. The business had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 24.94%.

Analyst Ratings Changes

ZBH has been the topic of several research reports. Citizens Jmp reduced their price target on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research report on Wednesday, April 29th. Leerink Partners started coverage on shares of Zimmer Biomet in a research report on Monday, April 13th. They set a “hold” rating and a $101.00 price objective for the company. Barclays dropped their price objective on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research note on Wednesday, April 29th. BMO Capital Markets assumed coverage on shares of Zimmer Biomet in a report on Wednesday, July 8th. They issued a “market perform” rating and a $95.00 target price on the stock. Finally, JPMorgan Chase & Co. lowered their price target on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $100.70.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.